A citation-based method for searching scientific literature

T Baert, A Ferrero, J Sehouli, D M O'Donnell, A González-Martín, F Joly, J van der Velden, P Blecharz, D S P Tan, D Querleu, N Colombo, A du Bois, J A Ledermann. Ann Oncol 2021
Times Cited: 4







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Image-guided ovarian mass biopsy: efficacy and safety.
Ashraf Thabet, Bhanusupriya Somarouthu, Esther Oliva, Debra A Gervais, Peter F Hahn, Susanna I Lee. J Vasc Interv Radiol 2014
10
25

Genital use of talc and risk of ovarian cancer: a meta-analysis.
Wera Berge, Kenneth Mundt, Hung Luu, Paolo Boffetta. Eur J Cancer Prev 2018
18
25

Are multidisciplinary teams in secondary care cost-effective? A systematic review of the literature.
K Melissa Ke, Jane M Blazeby, Sean Strong, Fran E Carroll, Andy R Ness, William Hollingworth. Cost Eff Resour Alloc 2013
47
25

Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983-2012.
Jinna Wu, Huanhuan Sun, Lewei Yang, Yun Deng, Yan Yan, Shuncong Wang, Guangwei Yang, Haiqing Ma. J Cancer 2018
11
25

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
705
25

Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis.
Laura J Havrilesky, Patricia G Moorman, William J Lowery, Jennifer M Gierisch, Remy R Coeytaux, Rachel Peragallo Urrutia, Michaela Dinan, Amanda J McBroom, Vic Hasselblad, Gillian D Sanders,[...]. Obstet Gynecol 2013
99
25

Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
Beverly Long, Jenny Chang, Argyrios Ziogas, Krishnansu S Tewari, Hoda Anton-Culver, Robert E Bristow. Am J Obstet Gynecol 2015
56
25

Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.
Innocenza Palaia, Federica Tomao, Carolina Maria Sassu, Lucia Musacchio, Pierluigi Benedetti Panici. Onco Targets Ther 2020
13
25

Predictive value of symptoms for early detection of ovarian cancer.
Mary Anne Rossing, Kristine G Wicklund, Kara L Cushing-Haugen, Noel S Weiss. J Natl Cancer Inst 2010
90
25

Impact of COVID-19 Pandemic on Ovarian Cancer Management: Adjusting to the New Normal.
Lizbeth Soto Jacome, Sachin Kumar Deshmukh, Padmamalini Thulasiraman, Nicolette Paolaungthong Holliday, Seema Singh. Cancer Manag Res 2021
2
50

Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Christina M Nagle, Jane E Francis, Anne E Nelson, Helen Zorbas, Karen Luxford, Anna de Fazio, Sian Fereday, David D Bowtell, Adèle C Green, Penelope M Webb. J Clin Oncol 2011
28
25

Symptoms associated with ovarian cancer.
Barbara Goff. Clin Obstet Gynecol 2012
36
25

Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.
C M Kurbacher, I A Cree, H W Bruckner, U Brenne, J A Kurbacher, K Müller, T Ackermann, T J Gilster, L M Wilhelm, H Engel,[...]. Anticancer Drugs 1998
95
25

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
615
25

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Christin Tse, Alexander R Shoemaker, Jessica Adickes, Mark G Anderson, Jun Chen, Sha Jin, Eric F Johnson, Kennan C Marsh, Michael J Mitten, Paul Nimmer,[...]. Cancer Res 2008
25


miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2.
Tianzi Hong, Jian Ding, Wenlian Li. Onco Targets Ther 2019
22
25

5-fluorouracil: mechanisms of action and clinical strategies.
Daniel B Longley, D Paul Harkin, Patrick G Johnston. Nat Rev Cancer 2003
25

Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.
Haiming Dai, Husheng Ding, X Wei Meng, Kevin L Peterson, Paula A Schneider, Judith E Karp, Scott H Kaufmann. Genes Dev 2015
32
25


Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
Lin Chen, Simon N Willis, Andrew Wei, Brian J Smith, Jamie I Fletcher, Mark G Hinds, Peter M Colman, Catherine L Day, Jerry M Adams, David C S Huang. Mol Cell 2005
25


Induction of apoptosis by cancer chemotherapy.
S H Kaufmann, W C Earnshaw. Exp Cell Res 2000
909
25

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Triona Ni Chonghaile, Kristopher A Sarosiek, Thanh-Trang Vo, Jeremy A Ryan, Anupama Tammareddi, Victoria Del Gaizo Moore, Jing Deng, Kenneth C Anderson, Paul Richardson, Yu-Tzu Tai,[...]. Science 2011
376
25

Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate.
Lei Hu, Meng Chen, Xueran Chen, Chenggang Zhao, Zhiyou Fang, Hongzhi Wang, Haiming Dai. Cell Death Dis 2020
25
25

Disposition study of procainamide and N-acetylprocainamide during subacute administration in rats.
B L Kamath, C M Lai, R W Krasula, H F Stampfli, S D Gupta, A Yacobi. Toxicol Appl Pharmacol 1982
8
25

Mitochondrial apoptosis and BH3 mimetics.
Haiming Dai, X Wei Meng, Scott H Kaufmann. F1000Res 2016
22
25

A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines.
A L Blajeski, T J Kottke, S H Kaufmann. Exp Cell Res 2001
65
25

Evaluation of the BH3-only protein Puma as a direct Bak activator.
Haiming Dai, Yuan-Ping Pang, Marina Ramirez-Alvarado, Scott H Kaufmann. J Biol Chem 2014
43
25

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Elisabet Wahlberg, Tobias Karlberg, Ekaterina Kouznetsova, Natalia Markova, Antonio Macchiarulo, Ann-Gerd Thorsell, Ewa Pol, Åsa Frostell, Torun Ekblad, Delal Öncü,[...]. Nat Biotechnol 2012
314
25

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
András Kotschy, Zoltán Szlavik, James Murray, James Davidson, Ana Leticia Maragno, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Gemma L Kelly, Jia-Nan Gong, Donia M Moujalled,[...]. Nature 2016
528
25

Cardiac dysfunction caused by purified human C3a anaphylatoxin.
U H del Balzo, R Levi, M J Polley. Proc Natl Acad Sci U S A 1985
97
25


Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
J D Leverson, H Zhang, J Chen, S K Tahir, D C Phillips, J Xue, P Nimmer, S Jin, M Smith, Y Xiao,[...]. Cell Death Dis 2015
302
25

Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.
P Bouillet, D Metcalf, D C Huang, D M Tarlinton, T W Kay, F Köntgen, J M Adams, A Strasser. Science 1999
25

Ovarian cancer.
Ursula A Matulonis, Anil K Sood, Lesley Fallowfield, Brooke E Howitt, Jalid Sehouli, Beth Y Karlan. Nat Rev Dis Primers 2016
313
25

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.
Toshiro Sato, Robert G Vries, Hugo J Snippert, Marc van de Wetering, Nick Barker, Daniel E Stange, Johan H van Es, Arie Abo, Pekka Kujala, Peter J Peters,[...]. Nature 2009
25

FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.
Andrew Sunters, Silvia Fernández de Mattos, Marie Stahl, Jan J Brosens, Georgia Zoumpoulidou, Catherine A Saunders, Paul J Coffer, René H Medema, R Charles Coombes, Eric W-F Lam. J Biol Chem 2003
402
25

Reflections on My Life with Taxol.
Susan Band Horwitz. Cell 2019
2
50

Tumorgrafts as in vivo surrogates for women with ovarian cancer.
S John Weroha, Marc A Becker, Sergio Enderica-Gonzalez, Sean C Harrington, Ann L Oberg, Matthew J Maurer, Sarah E Perkins, Mariam AlHilli, Kristina A Butler, Sarah McKinstry,[...]. Clin Cancer Res 2014
117
25



Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Annette T Byrne, Denis G Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K Chang,[...]. Nat Rev Cancer 2017
307
25

[Arrangements of new salaries].
N M Dufour. Infirm Can 1974
1
100

Precision medicine for metastatic breast cancer--limitations and solutions.
Monica Arnedos, Cecile Vicier, Sherene Loi, Celine Lefebvre, Stefan Michiels, Herve Bonnefoi, Fabrice Andre. Nat Rev Clin Oncol 2015
167
25

Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
Ting-Ting Tan, Kurt Degenhardt, Deirdre A Nelson, Brian Beaudoin, Wilberto Nieves-Neira, Philippe Bouillet, Andreas Villunger, Jerry M Adams, Eileen White. Cancer Cell 2005
227
25




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.